Zobrazeno 1 - 10
of 94
pro vyhledávání: '"Bernadette, Mannaerts"'
Autor:
Jane Alrø Bøtkjær, Stine Gry Kristensen, Hanna Ørnes Olesen, Per Larsson, Bernadette Mannaerts, Claus Yding Andersen
Publikováno v:
Frontiers in Endocrinology, Vol 15 (2024)
Externí odkaz:
https://doaj.org/article/7bda7d88fe394a81b09ac836df3c8ab7
Autor:
Bernadette Mannaerts, Ph.D.
Publikováno v:
F&S Reports, Vol 4, Iss 2, Pp 56-61 (2023)
Ganirelix is a gonadotropin-releasing hormone (GnRH) antagonist with high antagonistic activity that blocks the GnRH receptor by competitive binding. A daily dose of 0.25 mg of ganirelix was sel5ected after a phase II study because it was the minimal
Externí odkaz:
https://doaj.org/article/7b13d52f0dda4ec2823e37d36e3d9596
Autor:
Manuel Fernández Sánchez, Per Larsson, Marcos Ferrando Serrano, Ernesto Bosch, Juan Antonio García Velasco, Esther Santamaría López, Bernadette Mannaerts
Publikováno v:
Reproductive Biology and Endocrinology, Vol 21, Iss 1, Pp 1-8 (2023)
Abstract Purpose To explore the efficacy and safety of individualized follitropin delta dosing, based on serum anti-Müllerian hormone (AMH) concentration and bodyweight, in a long gonadotropin-releasing hormone (GnRH) agonist protocol. Methods Clini
Externí odkaz:
https://doaj.org/article/ec91af6547b141a88d00740139605261
Autor:
Rui Yang, Yunshan Zhang, Xiaoyan Liang, Xueru Song, Zhaolian Wei, Jianqiao Liu, Yezhou Yang, Jichun Tan, Qingxue Zhang, Yingpu Sun, Wei Wang, Weiping Qian, Lei Jin, Shuyu Wang, Yang Xu, Jing Yang, Marie Goethberg, Bernadette Mannaerts, Wen Wu, Zugeng Zheng, Jie Qiao
Publikováno v:
Reproductive Biology and Endocrinology, Vol 20, Iss 1, Pp 1-13 (2022)
Abstract Background To compare the efficacy and safety of follitropin delta in its individualized fixed-dose regimen with follitropin alfa in a conventional adjustable dosing regimen in Chinese women. Methods This was a subgroup analysis of the rando
Externí odkaz:
https://doaj.org/article/542c8d59ec0c4d1091523e71d72961fb
Autor:
Jane Alrø Bøtkjær, Stine Gry Kristensen, Hanna Ørnes Olesen, Per Larsson, Bernadette Mannaerts, Claus Yding Andersen
Publikováno v:
Frontiers in Endocrinology, Vol 13 (2022)
BackgroundChoriogonadotropin (CG) beta (FE 999302), a novel recombinant human (h)CG produced by a human cell line, has a longer half-life and higher potency than CG alfa produced by a Chinese hamster ovary cell line. hCG augments steroid production,
Externí odkaz:
https://doaj.org/article/350b23854d3044e8bf322e3918279c12
Autor:
Lars‐Erik Broksø Kyhl, Christiane Hesse, Per Larsson, Katharina Bruzelius, Bernadette Mannaerts
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 4, Pp 1590-1599 (2021)
Abstract The purpose of this first‐in‐human trial was to examine the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of a novel recombinant human chorionic gonadotropin (rhCG; FE 999302, choriogonadotropin beta) to support its clinical d
Externí odkaz:
https://doaj.org/article/b54ddc441b984e52b31454e1b9bfcfaf
Autor:
Manuel, Fernández Sánchez, Hana, Višnová, Per, Larsson, Claus, Yding Andersen, Marco, Filicori, Christophe, Blockeel, Anja, Pinborg, Yacoub, Khalaf, Bernadette, Mannaerts
Publikováno v:
on behalf of the Rainbow Study Group 2022, ' A randomized, controlled, first-in-patient trial of choriogonadotropin beta added to follitropin delta in women undergoing ovarian stimulation in a long GnRH agonist protocol ', Human Reproduction, vol. 37, no. 6, pp. 1161-1174 . https://doi.org/10.1093/humrep/deac061
STUDY QUESTION Does addition of choriogonadotropin beta (recombinant CG beta) to follitropin delta increase the number of good-quality blastocysts following ovarian stimulation in a long GnRH agonist protocol? SUMMARY ANSWER At the doses investigated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c065b2c823be71b308843ffcd29ff8ac
https://doi.org/10.1093/humrep/deac061
https://doi.org/10.1093/humrep/deac061
Autor:
Bjarke Mirner Klein, Enrico Papaleo, Hana Visnova, Bernadette Mannaerts, Katarzyna Kozioł, Fernando Sánchez Martin
Publikováno v:
Reproductive BioMedicine Online. 43:1019-1026
Research question How does the efficacy and safety of individualized follitropin delta dosing compare with conventional dosing for ovarian stimulation in potential high responders? Design Retrospective analysis of 153 potential high responders identi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e5976011c2b87274f4aa8b1aaaa6ad0e
https://doi.org/10.1016/j.rbmo.2021.08.024
https://doi.org/10.1016/j.rbmo.2021.08.024
Autor:
Runa Speer, Bernadette Mannaerts, Birgitte Buur Rasmussen, Per Larsson, Manuela Koch, Daniël M Jonker, Arjun Ravi
Publikováno v:
International Journal of Clinical Pharmacology and Therapeutics
Objective To determine whether serum human follicle-stimulating hormone (FSH) levels after single subcutaneous dosing of highly purified human menopausal gonadotropins (HP-hMG) in a liquid formulation and a powder formulation are bioequivalent. Mater
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e9378e76e2ff1a85d62856ef70ac8a8
http://europepmc.org/articles/PMC8594316
http://europepmc.org/articles/PMC8594316
Autor:
Joan-Carles Arce, Bernadette Mannaerts, Esther, Jon Havelock, Esther Trial Groups, Anna-Karina Aaris Henningsen
Publikováno v:
Journal of Assisted Reproduction and Genetics
Purpose To describe the pregnancy and neonatal outcomes using fresh and vitrified/warmed blastocysts obtained from ovarian stimulation with follitropin delta in controlled trials versus follitropin alfa. Methods This investigation evaluated the outco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8bf439012996d0304db9cb5b4026cbb0
https://doi.org/10.1007/s10815-021-02271-5
https://doi.org/10.1007/s10815-021-02271-5